<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Intraoperative use of antifibrinolytic agents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Intraoperative use of antifibrinolytic agents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Intraoperative use of antifibrinolytic agents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerrold H Levy, MD, FAHA, FCCM</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan B Mark, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Nussmeier, MD, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 17, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2286218207"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Fibrinolysis is an important physiologic response to bleeding that can contribute to coagulopathy. Prophylactic administration of an antifibrinolytic agent before surgery-induced tissue injury has occurred can reduce bleeding and allogeneic blood transfusions in cardiac surgery with cardiopulmonary bypass (CPB) and selected noncardiac procedures (eg, major orthopedic surgery, hepatic surgery). This topic will provide a review of the available intravenously (IV) administered antifibrinolytic agents (epsilon-aminocaproic acid [EACA], <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> [TXA], and aprotinin) and discuss their routine use in patients undergoing cardiac surgical procedures.</p><p>Prophylactic use of antifibrinolytics (primarily TXA) is also common during major orthopedic surgical elective procedures (eg, total knee or hip arthroplasty, spine surgery), as discussed in separate topic reviews. Antifibrinolytic therapy use after major trauma is discussed in the following topics:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/113837.html" rel="external">"Initial management of moderate to severe hemorrhage in the adult trauma patient", section on 'Antifibrinolytic agents'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/117817.html" rel="external">"Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'Tranexamic acid'</a>.)</p><p></p><p class="bulletIndent1">Other perioperative blood conservation strategies are discussed separately. (See  <a class="medical medical_review" href="/d/html/94347.html" rel="external">"Perioperative blood management: Strategies to minimize transfusions"</a>.)</p><p></p><p class="headingAnchor" id="H147877876"><span class="h1">AVAILABLE AGENTS</span><span class="headingEndMark"> — </span>Fibrinolysis (conversion of plasminogen to plasmin) has a central role in restoring blood vessel patency following clot formation (see  <a class="medical medical_review" href="/d/html/1326.html" rel="external">"Thrombotic and hemorrhagic disorders due to abnormal fibrinolysis", section on 'Overview of the fibrinolytic system'</a>). Notably, plasmin generation during fibrinolysis also activates proinflammatory pathways [<a href="#rid1">1</a>].</p><p>Epsilon-aminocaproic acid (EACA) and <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> (TXA) are small molecular weight pharmacologic agents that are widely used to inhibit fibrinolysis. They bind to the lysine attachment site of the plasminogen molecule to prevent its binding to fibrin and its conversion to plasmin, thereby inhibiting fibrinolysis.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epsilon-aminocaproic acid </strong>–<strong> </strong>EACA was one of the first intravenous (IV) antifibrinolytic agents developed. It is commonly used during cardiac surgery in the United States but is not available in many other countries due to concerns regarding renal dysfunction [<a href="#rid2">2-4</a>]. (See <a class="local">'Epsilon-aminocaproic acid-associated complications'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tranexamic acid</strong><strong> </strong>–<strong> </strong>TXA is the most widely used and extensively studied antifibrinolytic agent; it is used exclusively in most countries. TXA is approximately 10 times more potent than EACA [<a href="#rid5">5</a>].</p><p></p><p class="bulletIndent1">TXA is also available for topical administration to inhibit local fibrinolysis at the site of bleeding, reducing bleeding with minimal systemic effects. Details are discussed in a separate topic [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/d/html/15069.html" rel="external">"Overview of topical hemostatic agents and tissue adhesives", section on 'Tranexamic acid'</a>.)</p><p></p><p class="bulletIndent1">Oral preparations of TXA are also available. These have been used in major orthopedic surgical procedures. In studies of patients undergoing total knee arthroplasty, studies have noted similar efficacy after topical and/or oral administration of TXA compared with IV TXA, without differences in adverse effects [<a href="#rid7">7-17</a>] (see  <a class="medical medical_review" href="/d/html/116322.html" rel="external">"Anesthesia for total knee arthroplasty", section on 'Dosing regimen'</a>). Oral TXA is also used for treatment of menorrhagia when other options have been unsuccessful. (See  <a class="medical medical_review" href="/d/html/5415.html" rel="external">"Managing an episode of acute uterine bleeding", section on 'Tranexamic acid'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aprotinin</strong><strong> </strong>– Another antifibrinolytic agent, aprotinin, is a serine protease inhibitor. Aprotinin has been studied in cardiac and orthopedic surgery. Aprotinin is no longer available in the United States due to safety concerns [<a href="#rid18">18-20</a>]. However, aprotinin has been reintroduced for clinical use in Europe [<a href="#rid2">2,20-22</a>]. (See  <a class="medical medical_review" href="/d/html/1585.html" rel="external">"Early noncardiac complications of coronary artery bypass graft surgery", section on 'Antifibrinolytic agents'</a>.)</p><p></p><p class="headingAnchor" id="H1708990251"><span class="h1">POTENTIAL ADVERSE EFFECTS</span></p><p class="headingAnchor" id="H2184861116"><span class="h2">Thrombosis</span><span class="headingEndMark"> — </span>It is uncertain whether the administration of <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> (TXA) or epsilon-aminocaproic acid (EACA) increases the risk of thromboembolic events.<em> </em>Antifibrinolytic agents are clot stabilizers that facilitate the normal hemostatic response to bleeding. Although hypercoagulability is a theoretical concern [<a href="#rid2">2,23</a>], there are differences between prohemostatic and prothrombotic properties. In fact, in the absence of antifibrinolytic agents, fibrinolysis can have prothrombotic effects due to plasmin-mediated platelet activation and thrombin generation [<a href="#rid24">24</a>]. Furthermore, multiple agents with prothrombotic properties are often administered to patients with active surgical bleeding, including antifibrinolytic agents, transfusions, and factor concentrates.</p><p>A higher risk of thrombotic complications and death was noted in retrospective observational studies with another antifibrinolytic agent, aprotinin, leading to its withdrawal from the market in the United States [<a href="#rid18">18-20</a>].</p><p class="headingAnchor" id="H3369862294"><span class="h3">Average- versus high-risk patients</span><span class="headingEndMark"> — </span>Decisions regarding use of TXA or EACA in patients deemed at higher risk for thrombotic events should be individualized, taking into consideration patient-related and surgical procedure-related risks for bleeding and transfusion, as well as the individual's risk for thrombotic events.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Average-risk patients</strong> – Studies have not noted increased risk for thrombosis (eg, coronary graft occlusion, venous thromboembolism [VTE], pulmonary embolism) after routine prophylactic administration of antifibrinolytic agents during cardiac surgery [<a href="#rid20">20,25,26</a>], major joint arthroplasty (eg, total knee arthroplasty, total hip arthroplasty) [<a href="#rid7">7-17,23,27-44</a>], or spine surgery [<a href="#rid45">45-49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients at high baseline risk</strong> – Data regarding the safety of TXA for surgical patients at high baseline risk of thromboembolic events are somewhat limited. Randomized clinical trials of antifibrinolytic agents have commonly excluded patients with prior thromboembolic events due to concerns regarding exacerbation of risk. Such patients are often chronically receiving anticoagulant agents, which are typically withheld during the perioperative period. The limited available data include the following studies:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Orthopedic surgical patients with higher risk – Retrospective studies in orthopedic surgical patients with a prior thromboembolic history have not reported increased thromboembolic events or mortality after TXA administration [<a href="#rid23">23,32-40</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other types of noncardiac surgery – One randomized trial included 9535 patients undergoing various noncardiac surgical procedures [<a href="#rid50">50</a>]. Either TXA 1 gram intravenous (IV) bolus or placebo was administered at the start and again at the end of surgery. The composite primary outcome (life-threatening bleeding, major bleeding, or bleeding into a critical organ) was less frequent in the TXA group (9.1 versus 11.7 percent; hazard ratio [HR] 0.76, 95% CI 0.67-0.87). The composite cardiovascular safety outcome of postoperative myocardial injury, nonhemorrhagic stroke, peripheral arterial thrombosis, or symptomatic proximal VTE at 30 days differed little in the TXA group (14.2 percent) compared with the placebo group (13.9 percent; HR 1.02, 95% CI 0.92-1.14) [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with coronary stents undergoing surgical procedures – In one retrospective study, the risk for major adverse cardiac events did not appear to be increased after intraoperative administration of an antifibrinolytic agent in patients with coronary stents [<a href="#rid51">51</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Across varied settings – A systematic review that included 216 randomized trials of IV TXA versus placebo in 125,550 surgical and nonsurgical patients did not find an increased risk for thromboembolism in studies that included patients with a history of thromboembolism [<a href="#rid52">52</a>]. Also, thrombotic complications have not been noted after other routes of antifibrinolytic administration [<a href="#rid7">7-17</a>].</p><p></p><p class="headingAnchor" id="H2599810855"><span class="h3">Contraindications to antifibrinolysis</span><span class="headingEndMark"> — </span>However, we avoid administration of antifibrinolytic agents in certain patient groups due to the potential increased risk of thrombosis:</p><p class="bulletIndent1"><span class="glyph">●</span>Known hypercoagulable conditions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients undergoing vascular anastomosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of disseminated intravascular coagulation (DIC) – Although antifibrinolytic agents are appropriate in patients with severe bleeding due to a hyperfibrinolytic state, they are generally contraindicated in patients with DIC since inhibition of the fibrinolytic system may increase risk for thrombotic complications in this setting. (See  <a class="medical medical_review" href="/d/html/1306.html" rel="external">"Evaluation and management of disseminated intravascular coagulation (DIC) in adults", section on 'Avoid antifibrinolytic agents and PCCs'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Development of fibrinolytic shutdown – After major trauma, a potential concern is the risk of fibrinolytic shutdown, which increases the risk of thromboembolic complications due to an inhibition of fibrinolysis characterized by decreased tissue plasminogen activator (tPA) activity and increased circulating plasminogen activator inhibitor 1 (PAI-1) [<a href="#rid53">53</a>]. Diagnosis is with viscoelastic testing (eg, thromboelastography [TEG], rotational thromboelastometry [ROTEM]). In the United States (but not in Europe), antifibrinolytic agents are avoided after major trauma until these viscoelastic tests are available to guide administration of initial and additional doses, as discussed in separate topics [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients", section on 'Viscoelastic hemostatic assays'</a> and  <a class="medical medical_review" href="/d/html/15147.html" rel="external">"Etiology and diagnosis of coagulopathy in trauma patients", section on 'Fibrinolysis shutdown'</a> and  <a class="medical medical_review" href="/d/html/117817.html" rel="external">"Ongoing assessment, monitoring, and resuscitation of the severely injured patient", section on 'Management of acute traumatic coagulopathy'</a>.)</p><p></p><p class="headingAnchor" id="H1010491477"><span class="h2">Tranexamic acid-associated complications</span></p><p class="headingAnchor" id="H918450946"><span class="h3">Seizures</span><span class="headingEndMark"> — </span>Convulsive seizures have been reported after administration of high doses of IV TXA during cardiac surgery with cardiopulmonary bypass (CPB), although overall risk is low and is minimized by avoiding high doses (eg, &gt;4 grams) [<a href="#rid25">25,26,55-59</a>]. It is particularly important to avoid higher doses of TXA in patients with moderate to severe renal dysfunction who may accumulate higher blood levels of TXA [<a href="#rid60">60</a>]. Since TXA can pass into the cerebrospinal fluid, this agent is typically avoided in patients with a seizure history [<a href="#rid2">2,21</a>]. If available, we use EACA rather than TXA in patients with known history of seizures. If EACA is not available, decisions to use TXA are individualized based on procedure-related factors.</p><p>Data in cardiac surgical patients note a risk of seizures between 0.4 and 1.6 percent after administration of TXA [<a href="#rid2">2,25,26,55-57,59,61-63</a>]. In one randomized trial of 4631 patients undergoing cardiac surgery, seizures occurred in more patients who received TXA compared with placebo (0.7 versus 0.1 percent), but the overall risk was low [<a href="#rid25">25</a>]. A post hoc analysis noted that patients with seizures were more likely to have a stroke (relative risk [RR] 21.9, 95% CI 10.1-47.6) or die (RR 9.52, 95% CI 2.5-35.9) [<a href="#rid25">25</a>]. Another randomized trial in 3031 patients compared TXA dosing regimens during cardiac surgery (a 30 mg/kg bolus followed by 16 mg/kg per hour infusion plus 2 mg/kg in the CPB prime versus a 10 mg/kg bolus followed by a 2 mg/kg per hour infusion plus 1 mg/kg in the CPB prime) [<a href="#rid26">26</a>]. Seizure incidence was slightly higher in patients who received the higher TXA dose (1.0 versus 0.4 percent; risk difference [RD] 0.6 percent, 95% CI 0.0-1.2 percent). Older meta-analyses and observational studies have also noted that risk for seizures is higher after IV administration of higher doses of TXA compared with lower doses, controls, or other antifibrinolytic agents [<a href="#rid55">55,56,59</a>].</p><p>Potential mechanisms for seizures include induced neuronal excitation by TXA inhibition of γ-aminobutyric acid (GABA) neurotransmission [<a href="#rid62">62-64</a>]. During cardiac surgery, the occurrence of cerebral emboli may contribute to blood-brain barrier or ischemic injury and potential for seizure activity.</p><p class="headingAnchor" id="H2100447882"><span class="h3">Wrong site administration</span><span class="headingEndMark"> — </span>There have been multiple case reports of unintentional intrathecal administration of TXA, often attributed to the similar appearances of ampules of TXA and local anesthetic (particularly hyperbaric <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a> 0.5%) [<a href="#rid65">65,66</a>].</p><p>Reported signs and symptoms of intrathecal administration included back, buttock, and leg pain. Myoclonus, seizures, tachycardia, hypertension, and in some cases ventricular fibrillation have also been noted. Death occurred in approximately one-half of the reported cases. Vigilance is required when administering any pharmacologic agent during anesthetic care and is particularly important when neuraxial medications are used. (See  <a class="medical medical_review" href="/d/html/94596.html" rel="external">"Prevention of perioperative medication errors", section on 'Wrong route errors'</a>.)</p><p class="headingAnchor" id="H3614611658"><span class="h2">Epsilon-aminocaproic acid-associated complications</span></p><p class="headingAnchor" id="H2198655834"><span class="h3">Renal dysfunction</span><span class="headingEndMark"> — </span>Cases of postoperative renal dysfunction have been reported after EACA administration [<a href="#rid2">2,3</a>]. In a small randomized trial conducted in 64 consecutive adult patients undergoing thoracic aortic surgery with CPB, a numerically higher but nonsignificant increase in the incidence of renal failure was noted after EACA (3/30 patients) compared with TXA (0/31 patients) [<a href="#rid58">58</a>]. In a retrospective study of 448 children with<strong> </strong>life-threatening hemorrhage, most did not receive an antifibrinolytic [<a href="#rid4">4</a>]. Acute kidney injury (AKI) developed in 17 percent of those who received no antifibrinolytic agent, in 16 percent of 37 patients who received TXA, and in 50 percent of 18 patients who received EACA (adjusted odds ratio [OR] 3.3, 95% CI 1.0-10.3 for EACA compared with placebo).</p><p class="headingAnchor" id="H1007879507"><span class="h1">USE OF ANTIFIBRINOLYTIC AGENTS IN CARDIAC SURGERY</span><span class="headingEndMark"> — </span>We recommend administration of prophylactic antifibrinolytic therapy for cardiac surgery with cardiopulmonary bypass (CPB). This is consistent with several professional society guidelines [<a href="#rid67">67-71</a>].</p><p>Fibrinolysis is a major contributor to coagulopathy and bleeding during cardiac surgery with CPB  (<a class="graphic graphic_figure graphicRef120782" href="/d/graphic/120782.html" rel="external">figure 1</a>). Administration of intravenous (IV) antifibrinolytic agents is associated with decreased bleeding, allogeneic red blood cell (RBC) transfusions, and risk for postoperative mediastinal re-exploration in cardiac surgical patients [<a href="#rid1">1,2,18,20,23,25,26,52,59,72,73</a>].</p><p class="headingAnchor" id="H350995555"><span class="h2">Efficacy</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tranexamic acid</strong><strong> (TXA) </strong>–<strong> </strong>Most of the large studies and meta-analyses evaluating efficacy and safety of lysine analog antifibrinolytics in cardiac surgical patients are from studies of TXA [<a href="#rid18">18,20,25,26,52,59,73</a>]. In a placebo-controlled randomized trial of 4662 patients undergoing coronary artery bypass grafting (CABG) surgery, patients who received a bolus dose of TXA (either 100 or 50 mg/kg) administered 30 minutes after anesthesia induction had a lower rate of blood transfusion (37.9 versus 54.7 percent; risk ratio 0.69, 95% CI 0.65-0.74) [<a href="#rid25">25</a>]. Major hemorrhage or cardiac tamponade leading to reoperation was also less common (1.4 versus 2.8 percent; risk ratio 0.49, 95% CI 0.32-0.75). Although rare, seizures were more common in the TXA group (0.7 versus 0.1 percent) [<a href="#rid25">25</a>].</p><p></p><p class="bulletIndent1">A 2021 model-based meta-analysis of 64 randomized trials and 18 observational studies included nearly 50,000 cardiac surgical patients and 73 different dosing regimens of TXA (ranging from 5.5 mg/kg to 20 grams total) [<a href="#rid59">59</a>]. The estimated probability of transfusion in the absence of TXA exposure was 62 percent (95% CI 53-72 percent). Both lower and higher dosing regimens reduced transfusion risk, with a maximum reduction of 33 percent (95% CI 25-42 percent) [<a href="#rid59">59</a>]. Another meta-analysis of placebo-controlled trials in patients undergoing cardiac surgery, major noncardiac surgery, or nonsurgical medical interventions noted that TXA reduced mortality due to bleeding (2.9 versus 3.8 percent; risk difference [RD] 0.008, 95% CI 0.011-0.005; 46,702 patients; 49 studies) [<a href="#rid52">52</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epsilon-aminocaproic acid (EACA) </strong>–<strong> </strong>Data regarding efficacy of EACA are more limited. A 2009 meta-analysis of randomized trials of the three antifibrinolytic agents (aprotinin, TXA, and EACA) included only cardiac surgical patients, with 5 trials (672 patients) comparing EACA versus controls, and 19 trials (1802 patients) comparing TXA versus controls [<a href="#rid18">18</a>]. Similar efficacy of both agents was reported; compared with placebo, relative risk for TXA was 0.70 (95% CI 0.61-0.80) and for EACA was 0.75 (95% CI 0.58-0.96).</p><p></p><p class="bulletIndent1">A post hoc analysis of a 2011 study in cardiac surgical patients included direct comparisons of those receiving EACA (n = 780) versus those receiving TXA (n = 770) [<a href="#rid74">74</a>]. Risks for bleeding requiring reoperation and requirements for transfusion of blood products were similar except for fresh frozen plasma (FFP); 37.8 percent of patients receiving TXA needed FFP compared with 45.4 percent of those receiving EACA (relative risk 0.83, 98.33% CI 0.72-0.96).</p><p></p><p class="bulletIndent1">A 2011 meta-analyses (52 randomized trials; 25,000 participants) reported efficacy of three antifibrinolytic agents (aprotinin, TXA, and EACA) compared with placebo in various types of cardiac and noncardiac surgery [<a href="#rid20">20</a>]. Overall, RBC transfusions were less frequent in patients receiving TXA compared with EACA (30 versus 45 percent); relative risk compared with placebo for TXA was 0.61 (95% CI 0.53-0.70) and for EACA was 0.81 (95% CI 0.67-0.99).</p><p></p><p class="headingAnchor" id="H591048730"><span class="h2">Timing of administration</span><span class="headingEndMark"> — </span>The antifibrinolytic agent is typically administered after anesthetic induction and always before initiation of CPB [<a href="#rid2">2,75,76</a>]. However, institutional protocols for precise timing of initial administration vary. Examples include just before skin incision, over a 30-minute period after anesthetic induction, or shortly after systemic heparinization. Administration of prophylactic antifibrinolytic agents before the occurrence of significant tissue injury is ideal but not always feasible (eg, traumatic cardiac injury).</p><p>The antifibrinolytic infusion is continued throughout the postbypass period until the completion of the procedure (ie, skin closure). If ongoing clinical bleeding is a concern, we continue the antifibrinolytic infusion for several postoperative hours [<a href="#rid2">2,25,76-79</a>].</p><p class="headingAnchor" id="H3949095322"><span class="h2">Dosing and administration</span></p><p class="headingAnchor" id="H383688047"><span class="h3">Tranexamic acid</span><span class="headingEndMark"> — </span>Typically, 10 to 30 mg/kg of IV TXA is administered as an initial loading dose, followed by an infusion of 1 to 16 mg/kg per hour throughout CPB until skin closure. Some centers include a dose of 1 to 2 mg/kg in the CPB prime. In patients with normal renal function, the half-life is approximately 80 minutes after the bolus dose. For this reason, the infusion is continued until the end of surgery or longer if necessary [<a href="#rid2">2</a>]. (See <a class="local">'Timing of administration'</a> above.)</p><p>Various other dosing strategies have been reported  (<a class="graphic graphic_figure graphicRef142439" href="/d/graphic/142439.html" rel="external">figure 2</a>) [<a href="#rid79">79</a>]. Although the IV dose of TXA required to inhibit fibrinolytic activity by 98 to 100 percent is approximately 100 mcg/mL, a lower dose of 22.4 mcg/mL provides an 80 percent effective concentration [<a href="#rid59">59</a>]. Once the concentration exceeds the 80 percent effective concentration, further changes in drug concentration have little clinically relevant impact on efficacy [<a href="#rid20">20</a>]. For example, a randomized trial compared TXA dosing regimens in 3031 patients undergoing cardiac surgery (a 30 mg/kg bolus followed by 16 mg/kg per hour infusion plus 2 mg/kg in the CPB prime versus a 10 mg/kg bolus followed by a 2 mg/kg per hour infusion plus 1 mg/kg in the CPB prime) [<a href="#rid26">26</a>]. Only a slightly lower incidence of allogeneic blood transfusion was noted in patients receiving the higher TXA dose (21.8 versus 26.0 percent) [<a href="#rid26">26</a>]. However, as noted above, the seizure incidence was slightly higher in those receiving the higher TXA dose (1.0 versus 0.4 percent) [<a href="#rid26">26</a>]. (See <a class="local">'Seizures'</a> above.)</p><p class="headingAnchor" id="H3432687465"><span class="h3">Epsilon-aminocaproic acid</span><span class="headingEndMark"> — </span>Typically, an initial loading dose of 5 to 10 grams is followed by a continuous infusion of 1 gram/hour to maintain plasma concentration of approximately 0.13 mg/mL [<a href="#rid79">79</a>]. Some centers include an additional 5 to 10 mg dose in the CPB prime. Other dosing strategies have been reported [<a href="#rid79">79-81</a>].</p><p></p><p class="headingAnchor" id="H1475017549"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/120167.html" rel="external">"Society guideline links: Transfusion and patient blood management"</a>.)</p><p class="headingAnchor" id="H2218311892"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Available agents </strong>–<strong> </strong>In intraoperative settings, epsilon-aminocaproic acid (EACA) and <a class="drug drug_general" data-topicid="10011" href="/d/drug information/10011.html" rel="external">tranexamic acid</a> (TXA) are the two widely used intravenous (IV) agents that inhibit fibrinolysis. (See <a class="local">'Available agents'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>EACA </strong>– EACA is commonly used during cardiac surgery in the United States.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TXA </strong>– TXA is used in most other settings and is used exclusively in many countries. TXA is approximately 10-fold more potent than EACA.</p><p></p><p class="bulletIndent2">TXA is also available for oral administration, and in topical preparations to inhibit local fibrinolysis at the site of bleeding. (See  <a class="medical medical_review" href="/d/html/15069.html" rel="external">"Overview of topical hemostatic agents and tissue adhesives", section on 'Tranexamic acid'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Aprotinin</strong><strong> </strong>–<strong> </strong>Another antifibrinolytic agent, aprotinin, is no longer available in the United States and is rarely used elsewhere due to safety concerns.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential adverse effects</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Thrombosis </strong>–<strong> </strong>Although hypercoagulability is a theoretical concern, increased thrombosis risk (eg, coronary graft occlusion, venous thromboembolism [VTE], pulmonary embolism) has not been noted after routine prophylactic administration of antifibrinolytic agents during cardiac surgery, during noncardiac surgery such as major orthopedic procedures, or in nonsurgical settings.</p><p></p><p class="bulletIndent2">However, we avoid IV antifibrinolytics in patients with a known hypercoagulable condition, those undergoing vascular anastomosis, and after development of disseminated intravascular coagulation (DIC) or trauma-induced fibrinolytic shutdown. (See <a class="local">'Thrombosis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>TXA-associated complications</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Seizures with high doses of TXA</strong> – Convulsive seizures have been reported after administration of higher doses of TXA (eg, &gt;4 grams) during cardiac surgery. Patients with moderate to severe renal dysfunction are at particular risk because they may accumulate higher blood levels of TXA. (See <a class="local">'Seizures'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Wrong site administration </strong>–<strong> </strong>Inadvertent intrathecal administration of TXA has occurred due to the similar appearances of ampules of TXA and hyperbaric <a class="drug drug_general" data-topicid="9169" href="/d/drug information/9169.html" rel="external">bupivacaine</a>, causing severe adverse effects. (See <a class="local">'Wrong site administration'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>EACA-associated renal dysfunction</strong> – Rare cases of postoperative renal injury have been reported after IV EACA administration. (See <a class="local">'Epsilon-aminocaproic acid-associated complications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Use of antifibrinolytic agents in cardiac surgery</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend administration of prophylactic antifibrinolytic therapy (EACA or TXA) before initiation of cardiopulmonary bypass (CPB) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). We administer an initial loading dose followed by an infusion continuing throughout CPB until skin closure. If ongoing clinical bleeding is a concern, we continue the infusion for several postoperative hours. Randomized trials demonstrate that such treatment reduces risks for perioperative transfusion and postoperative mediastinal re-exploration. (See <a class="local">'Timing of administration'</a> above and <a class="local">'Efficacy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dosing and administration</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>TXA </strong>–<strong> </strong>Typically, an initial loading dose of 10 to 30 mg/kg is administered, followed by an infusion of 1 to 16 mg/kg per hour. Some centers include a dose of 1 to 2 mg/kg in the CPB prime. Various other dosing strategies have been reported  (<a class="graphic graphic_figure graphicRef142439" href="/d/graphic/142439.html" rel="external">figure 2</a>). (See <a class="local">'Tranexamic acid'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>EACA </strong>– Typically, an initial loading dose of 5 to 10 grams is administered, followed by a continuous infusion of 1 gram/hour. Some centers include a dose of 5 to 10 grams in the CPB prime. (See <a class="local">'Epsilon-aminocaproic acid'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Levy JH. Antifibrinolytic therapy: new data and new concepts. Lancet 2010; 376:3.</a></li><li><a class="nounderline abstract_t">Levy JH, Koster A, Quinones QJ, et al. Antifibrinolytic Therapy and Perioperative Considerations. Anesthesiology 2018; 128:657.</a></li><li><a class="nounderline abstract_t">Manjunath G, Fozailoff A, Mitcheson D, Sarnak MJ. Epsilon-aminocaproic acid and renal complications: case report and review of the literature. Clin Nephrol 2002; 58:63.</a></li><li><a class="nounderline abstract_t">Kolodziej JH, Leeper CM, Leonard JC, et al. Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children. Transfusion 2023; 63 Suppl 3:S26.</a></li><li><a class="nounderline abstract_t">Tengborn L, Blombäck M, Berntorp E. Tranexamic acid--an old drug still going strong and making a revival. Thromb Res 2015; 135:231.</a></li><li><a class="nounderline abstract_t">Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev 2013; :CD010562.</a></li><li><a class="nounderline abstract_t">DeFrancesco CJ, Reichel JF, Gbaje E, et al. Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial. Br J Anaesth 2023; 130:234.</a></li><li><a class="nounderline abstract_t">Jules-Elysee KM, Tseng A, Sculco TP, et al. Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels. J Bone Joint Surg Am 2019.</a></li><li><a class="nounderline abstract_t">Abdel MP, Chalmers BP, Taunton MJ, et al. Intravenous Versus Topical Tranexamic Acid in Total Knee Arthroplasty: Both Effective in a Randomized Clinical Trial of 640 Patients. J Bone Joint Surg Am 2018; 100:1023.</a></li><li><a class="nounderline abstract_t">Guo P, He Z, Wang Y, et al. Efficacy and safety of oral tranexamic acid in total knee arthroplasty: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97:e0587.</a></li><li><a class="nounderline abstract_t">Fillingham YA, Ramkumar DB, Jevsevar DS, et al. The Efficacy of Tranexamic Acid in Total Knee Arthroplasty: A Network Meta-Analysis. J Arthroplasty 2018; 33:3090.</a></li><li><a class="nounderline abstract_t">Zhu J, Zhu Y, Lei P, et al. Efficacy and safety of tranexamic acid in total hip replacement: A PRISMA-compliant meta-analysis of 25 randomized controlled trials. Medicine (Baltimore) 2017; 96:e9552.</a></li><li><a class="nounderline abstract_t">Wang H, Shen B, Zeng Y. Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials. Knee 2014; 21:987.</a></li><li><a class="nounderline abstract_t">Tian P, Liu WB, Li ZJ, et al. The efficacy and safety of tranexamic acid in revision total knee arthroplasty: a meta-analysis. BMC Musculoskelet Disord 2017; 18:273.</a></li><li><a class="nounderline abstract_t">Lin C, Qi Y, Jie L, et al. Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis. Medicine (Baltimore) 2016; 95:e5344.</a></li><li><a class="nounderline abstract_t">Yang L, Du S, Sun Y. Is combined topical and intravenous tranexamic acid superior to single use of tranexamic acid in total joint arthroplasty?: A meta-analysis from randomized controlled trials. Medicine (Baltimore) 2017; 96:e7609.</a></li><li><a class="nounderline abstract_t">Wang Z, Shen X. The efficacy of combined intra-articular and intravenous tranexamic acid for blood loss in primary total knee arthroplasty: A meta-analysis. Medicine (Baltimore) 2017; 96:e8123.</a></li><li><a class="nounderline abstract_t">Henry D, Carless P, Fergusson D, Laupacis A. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 2009; 180:183.</a></li><li><a class="nounderline abstract_t">Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358:2319.</a></li><li><a class="nounderline abstract_t">Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011; :CD001886.</a></li><li><a class="nounderline abstract_t">Gerstein NS, Brierley JK, Windsor J, et al. Antifibrinolytic Agents in Cardiac and Noncardiac Surgery: A Comprehensive Overview and Update. J Cardiothorac Vasc Anesth 2017; 31:2183.</a></li><li><a class="nounderline abstract_t">De Hert S, Ouattara A, Royston D, et al. Use and safety of aprotinin in routine clinical practice: A European postauthorisation safety study conducted in patients undergoing cardiac surgery. Eur J Anaesthesiol 2022; 39:685.</a></li><li><a class="nounderline abstract_t">Patel PA, Wyrobek JA, Butwick AJ, et al. Update on Applications and Limitations of Perioperative Tranexamic Acid. Anesth Analg 2022; 135:460.</a></li><li><a class="nounderline abstract_t">Aronson DL, Chang P, Kessler CM. Platelet-dependent thrombin generation after in vitro fibrinolytic treatment. Circulation 1992; 85:1706.</a></li><li><a class="nounderline abstract_t">Myles PS, Smith JA, Forbes A, et al. Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery. N Engl J Med 2017; 376:136.</a></li><li><a class="nounderline abstract_t">Shi J, Zhou C, Pan W, et al. Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial. JAMA 2022; 328:336.</a></li><li><a class="nounderline abstract_t">Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br 2011; 93:39.</a></li><li><a class="nounderline abstract_t">Alshryda S, Sarda P, Sukeik M, et al. Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br 2011; 93:1577.</a></li><li><a class="nounderline abstract_t">Yang ZG, Chen WP, Wu LD. Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis. J Bone Joint Surg Am 2012; 94:1153.</a></li><li><a class="nounderline abstract_t">Alshryda S, Sukeik M, Sarda P, et al. A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement. Bone Joint J 2014; 96-B:1005.</a></li><li><a class="nounderline abstract_t">Wei Z, Liu M. The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases. Transfus Med 2015; 25:151.</a></li><li><a class="nounderline abstract_t">Fillingham YA, Ramkumar DB, Jevsevar DS, et al. The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis. J Arthroplasty 2018; 33:3070.</a></li><li><a class="nounderline abstract_t">Poeran J, Rasul R, Suzuki S, et al. Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ 2014; 349:g4829.</a></li><li><a class="nounderline abstract_t">Pavenski K, Ward SE, Hare GMT, et al. A rationale for universal tranexamic acid in major joint arthroplasty: overall efficacy and impact of risk factors for transfusion. Transfusion 2019; 59:207.</a></li><li><a class="nounderline abstract_t">Sabbag OD, Abdel MP, Amundson AW, et al. Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study. J Arthroplasty 2017; 32:S246.</a></li><li><a class="nounderline abstract_t">Duncan CM, Gillette BP, Jacob AK, et al. Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty. J Arthroplasty 2015; 30:272.</a></li><li><a class="nounderline abstract_t">Whiting DR, Gillette BP, Duncan C, et al. Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities. Clin Orthop Relat Res 2014; 472:66.</a></li><li><a class="nounderline abstract_t">Poeran J, Chan JJ, Zubizarreta N, et al. Safety of Tranexamic Acid in Hip and Knee Arthroplasty in High-risk Patients. Anesthesiology 2021; 135:57.</a></li><li><a class="nounderline abstract_t">Zak SG, Tang A, Sharan M, et al. Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty. J Bone Joint Surg Am 2021; 103:900.</a></li><li><a class="nounderline abstract_t">Porter SB, White LJ, Osagiede O, et al. Tranexamic Acid Administration Is Not Associated With an Increase in Complications in High-Risk Patients Undergoing Primary Total Knee or Total Hip Arthroplasty: A Retrospective Case-Control Study of 38,220 Patients. J Arthroplasty 2020; 35:45.</a></li><li><a class="nounderline abstract_t">Hines JT, Petis SM, Amundson AW, et al. Intravenous Tranexamic Acid Safely and Effectively Reduces Transfusion Rates in Revision Total Knee Arthroplasties. J Bone Joint Surg Am 2020; 102:381.</a></li><li><a class="nounderline abstract_t">Barrachina B, Lopez-Picado A, Remon M, et al. Tranexamic Acid Compared with Placebo for Reducing Total Blood Loss in Hip Replacement Surgery: A Randomized Clinical Trial. Anesth Analg 2016; 122:986.</a></li><li><a class="nounderline abstract_t">Hsu CH, Lin PC, Kuo FC, Wang JW. A regime of two intravenous injections of tranexamic acid reduces blood loss in minimally invasive total hip arthroplasty: a prospective randomised double-blind study. Bone Joint J 2015; 97-B:905.</a></li><li><a class="nounderline abstract_t">Zhang P, He J, Fang Y, et al. Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: A meta-analysis. Medicine (Baltimore) 2017; 96:e6940.</a></li><li><a class="nounderline abstract_t">Liu ZG, Yang F, Zhu YH, et al. Is Tranexamic Acid Beneficial in Open Spine Surgery? and its Effects Vary by Dosage, Age, Sites, and Locations: A Meta-Analysis of Randomized Controlled Trials. World Neurosurg 2022; 166:141.</a></li><li><a class="nounderline abstract_t">Berenholtz SM, Pham JC, Garrett-Mayer E, et al. Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery. Spine (Phila Pa 1976) 2009; 34:2096.</a></li><li><a class="nounderline abstract_t">Gill JB, Chin Y, Levin A, Feng D. The use of antifibrinolytic agents in spine surgery. A meta-analysis. J Bone Joint Surg Am 2008; 90:2399.</a></li><li><a class="nounderline abstract_t">Li G, Sun TW, Luo G, Zhang C. Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis. Eur Spine J 2017; 26:140.</a></li><li><a class="nounderline abstract_t">Soroceanu A, Oren JH, Smith JS, et al. Effect of Antifibrinolytic Therapy on Complications, Thromboembolic Events, Blood Product Utilization, and Fusion in Adult Spinal Deformity Surgery. Spine (Phila Pa 1976) 2016; 41:E879.</a></li><li><a class="nounderline abstract_t">Devereaux PJ, Marcucci M, Painter TW, et al. Tranexamic Acid in Patients Undergoing Noncardiac Surgery. N Engl J Med 2022; 386:1986.</a></li><li><a class="nounderline abstract_t">Boswell MR, Smith MM, Frank RD, et al. Association Between Antifibrinolytic Therapy and Perioperative Outcomes in Patients With Coronary Artery Stents Undergoing Noncardiac Surgery. Anesth Analg 2021; 132:1635.</a></li><li><a class="nounderline abstract_t">Taeuber I, Weibel S, Herrmann E, et al. Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression. JAMA Surg 2021; :e210884.</a></li><li><a class="nounderline abstract_t">Moore HB, Moore EE, Neal MD, et al. Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications. Anesth Analg 2019; 129:762.</a></li><li><a class="nounderline abstract_t">Chang R, Cardenas JC, Wade CE, Holcomb JB. Advances in the understanding of trauma-induced coagulopathy. Blood 2016; 128:1043.</a></li><li><a class="nounderline abstract_t">Takagi H, Ando T, Umemoto T, All-Literature Investigation of Cardiovascular Evidence (ALICE) group. Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and non-randomized studies. J Cardiovasc Surg (Torino) 2017; 58:633.</a></li><li><a class="nounderline abstract_t">Couture P, Lebon JS, Laliberté É, et al. Low-Dose Versus High-Dose Tranexamic Acid Reduces the Risk of Nonischemic Seizures After Cardiac Surgery With Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2017; 31:1611.</a></li><li><a class="nounderline abstract_t">Murkin JM, Falter F, Granton J, et al. High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010; 110:350.</a></li><li><a class="nounderline abstract_t">Makhija N, Sarupria A, Kumar Choudhary S, et al. Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety. J Cardiothorac Vasc Anesth 2013; 27:1201.</a></li><li><a class="nounderline abstract_t">Zufferey PJ, Lanoiselée J, Graouch B, et al. Exposure-Response Relationship of Tranexamic Acid in Cardiac Surgery. Anesthesiology 2021; 134:165.</a></li><li><a class="nounderline abstract_t">Jerath A, Yang QJ, Pang KS, et al. Tranexamic Acid Dosing for Cardiac Surgical Patients With Chronic Renal Dysfunction: A New Dosing Regimen. Anesth Analg 2018; 127:1323.</a></li><li><a class="nounderline abstract_t">Koster A, Levy JH. Understanding Potential Drug Side Effects: Can We Translate Molecular Mechanisms to Clinical Applications? Anesthesiology 2017; 127:6.</a></li><li><a class="nounderline abstract_t">Lecker I, Wang DS, Whissell PD, et al. Tranexamic acid-associated seizures: Causes and treatment. Ann Neurol 2016; 79:18.</a></li><li><a class="nounderline abstract_t">Kratzer S, Irl H, Mattusch C, et al. Tranexamic acid impairs γ-aminobutyric acid receptor type A-mediated synaptic transmission in the murine amygdala: a potential mechanism for drug-induced seizures? Anesthesiology 2014; 120:639.</a></li><li><a class="nounderline abstract_t">Lecker I, Wang DS, Romaschin AD, et al. Tranexamic acid concentrations associated with human seizures inhibit glycine receptors. J Clin Invest 2012; 122:4654.</a></li><li><a class="nounderline abstract_t">Patel S, Robertson B, McConachie I. Catastrophic drug errors involving tranexamic acid administered during spinal anaesthesia. Anaesthesia 2019; 74:904.</a></li><li class="breakAll">www.accessdata.fda.gov/drugsatfda_docs/label/2021/019281s047lbl.pdf.</li><li><a class="nounderline abstract_t">Raphael J, Mazer CD, Subramani S, et al. Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. Anesth Analg 2019; 129:1209.</a></li><li><a class="nounderline abstract_t">Society of Thoracic Surgeons Blood Conservation Guideline Task Force, Ferraris VA, Brown JR, et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011; 91:944.</a></li><li><a class="nounderline abstract_t">Wahba A, Milojevic M, Boer C, et al. 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery. Eur J Cardiothorac Surg 2020; 57:210.</a></li><li><a class="nounderline abstract_t">Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C, Meesters MI, et al. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth 2018; 32:88.</a></li><li><a class="nounderline abstract_t">Tibi P, McClure RS, Huang J, et al. STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management. J Cardiothorac Vasc Anesth 2021; 35:2569.</a></li><li><a class="nounderline abstract_t">Hessel EA 2nd. What's New in Cardiopulmonary Bypass. J Cardiothorac Vasc Anesth 2019; 33:2296.</a></li><li><a class="nounderline abstract_t">Maeda T, Ishihara T, Miyata S, et al. Evaluating the Effect on Mortality of a No-Tranexamic acid (TXA) Policy for Cardiovascular Surgery. J Cardiothorac Vasc Anesth 2018; 32:1627.</a></li><li><a class="nounderline abstract_t">Raghunathan K, Connelly NR, Kanter GJ. ε-Aminocaproic acid and clinical value in cardiac anesthesia. J Cardiothorac Vasc Anesth 2011; 25:16.</a></li><li><a class="nounderline abstract_t">Spence J, Long S, Tidy A, et al. Tranexamic Acid Administration During On-Pump Cardiac Surgery: A Survey of Current Practices Among Canadian Anesthetists Working in Academic Centers. Anesth Analg 2017; 125:1863.</a></li><li><a class="nounderline abstract_t">Falana O, Patel G. Efficacy and safety of tranexamic acid versus ϵ-aminocaproic acid in cardiovascular surgery. Ann Pharmacother 2014; 48:1563.</a></li><li><a class="nounderline abstract_t">Lier H, Maegele M, Shander A. Tranexamic Acid for Acute Hemorrhage: A Narrative Review of Landmark Studies and a Critical Reappraisal of Its Use Over the Last Decade. Anesth Analg 2019; 129:1574.</a></li><li><a class="nounderline abstract_t">McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012; 72:585.</a></li><li><a class="nounderline abstract_t">Koster A, Faraoni D, Levy JH. Antifibrinolytic Therapy for Cardiac Surgery: An Update. Anesthesiology 2015; 123:214.</a></li><li><a class="nounderline abstract_t">Kikura M, Levy JH, Tanaka KA, Ramsay JG. A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery. J Am Coll Surg 2006; 202:216.</a></li><li><a class="nounderline abstract_t">Bennett-Guerrero E, Sorohan JG, Gurevich ML, et al. Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. Anesthesiology 1997; 87:1373.</a></li></ol></div><div id="topicVersionRevision">Topic 140949 Version 8.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20554318" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antifibrinolytic therapy: new data and new concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29200009" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Antifibrinolytic Therapy and Perioperative Considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12141409" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Epsilon-aminocaproic acid and renal complications: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37070413" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Epsilon aminocaproic acid is associated with acute kidney injury after life-threatening hemorrhage in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25559460" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Tranexamic acid--an old drug still going strong and making a revival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23881695" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Topical application of tranexamic acid for the reduction of bleeding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36526484" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effectiveness of oral versus intravenous tranexamic acid in primary total hip and knee arthroplasty: a randomised, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31567680" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of Topical and Intravenous Tranexamic Acid for Total Knee Replacement: A Randomized Double-Blinded Controlled Study of Effects on Tranexamic Acid Levels and Thrombogenic and Inflammatory Marker Levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29916929" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Intravenous Versus Topical Tranexamic Acid in Total Knee Arthroplasty: Both Effective in a Randomized Clinical Trial of 640 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29718858" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Efficacy and safety of oral tranexamic acid in total knee arthroplasty: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29805106" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The Efficacy of Tranexamic Acid in Total Knee Arthroplasty: A Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29384974" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Efficacy and safety of tranexamic acid in total hip replacement: A PRISMA-compliant meta-analysis of 25 randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25450009" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparison of topical versus intravenous tranexamic acid in primary total knee arthroplasty: a meta-analysis of randomized controlled and prospective cohort trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28637438" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : The efficacy and safety of tranexamic acid in revision total knee arthroplasty: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28002321" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Is combined topical with intravenous tranexamic acid superior than topical, intravenous tranexamic acid alone and control groups for blood loss controlling after total knee arthroplasty: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28746213" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Is combined topical and intravenous tranexamic acid superior to single use of tranexamic acid in total joint arthroplasty?: A meta-analysis from randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29049195" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The efficacy of combined intra-articular and intravenous tranexamic acid for blood loss in primary total knee arthroplasty: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19050037" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18480196" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21412876" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28457777" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antifibrinolytic Agents in Cardiac and Noncardiac Surgery: A Comprehensive Overview and Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35766393" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Use and safety of aprotinin in routine clinical practice: A European postauthorisation safety study conducted in patients undergoing cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35977357" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Update on Applications and Limitations of Perioperative Tranexamic Acid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1533349" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Platelet-dependent thrombin generation after in vitro fibrinolytic treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27774838" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Tranexamic Acid in Patients Undergoing Coronary-Artery Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35881121" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21196541" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22161917" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Tranexamic acid in total knee replacement: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22623147" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effectiveness and safety of tranexamic acid in reducing blood loss in total knee arthroplasty: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25086114" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A systematic review and meta-analysis of the topical administration of tranexamic acid in total hip and knee replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26033447" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The effectiveness and safety of tranexamic acid in total hip or knee arthroplasty: a meta-analysis of 2720 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29699826" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Safety of Tranexamic Acid in Total Joint Arthroplasty: A Direct Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25116268" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30383292" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A rationale for universal tranexamic acid in major joint arthroplasty: overall efficacy and impact of risk factors for transfusion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28262452" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Tranexamic Acid Was Safe in Arthroplasty Patients With a History of Venous Thromboembolism: A Matched Outcome Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25257237" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Venous thromboembolism and mortality associated with tranexamic acid use during total hip and knee arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23817754" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Preliminary results suggest tranexamic acid is safe and effective in arthroplasty patients with severe comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33857300" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Safety of Tranexamic Acid in Hip and Knee Arthroplasty in High-risk Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33983147" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Tranexamic Acid Is Safe in Patients with a History of Coronary Artery Disease Undergoing Total Joint Arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31522854" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Tranexamic Acid Administration Is Not Associated With an Increase in Complications in High-Risk Patients Undergoing Primary Total Knee or Total Hip Arthroplasty: A Retrospective Case-Control Study of 38,220 Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31977819" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Intravenous Tranexamic Acid Safely and Effectively Reduces Transfusion Rates in Revision Total Knee Arthroplasties.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26991616" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Tranexamic Acid Compared with Placebo for Reducing Total Blood Loss in Hip Replacement Surgery: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26130344" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A regime of two intravenous injections of tranexamic acid reduces blood loss in minimally invasive total hip arthroplasty: a prospective randomised double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28538384" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Efficacy and safety of intravenous tranexamic acid administration in patients undergoing hip fracture surgery for hemostasis: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35843575" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Is Tranexamic Acid Beneficial in Open Spine Surgery? and its Effects Vary by Dosage, Age, Sites, and Locations: A Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19730217" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effect of epsilon aminocaproic acid on red-cell transfusion requirements in major spinal surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18978408" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The use of antifibrinolytic agents in spine surgery. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27671279" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy of antifibrinolytic agents on surgical bleeding and transfusion requirements in spine surgery: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27398796" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of Antifibrinolytic Therapy on Complications, Thromboembolic Events, Blood Product Utilization, and Fusion in Adult Spinal Deformity Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35363452" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Tranexamic Acid in Patients Undergoing Noncardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33780399" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Association Between Antifibrinolytic Therapy and Perioperative Outcomes in Patients With Coronary Artery Stents Undergoing Noncardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33851983" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Association of Intravenous Tranexamic Acid With Thromboembolic Events and Mortality: A Systematic Review, Meta-analysis, and Meta-regression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31425218" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Fibrinolysis Shutdown in Trauma: Historical Review and Clinical Implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27381903" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Advances in the understanding of trauma-induced coagulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263046" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Seizures associated with tranexamic acid for cardiac surgery: a meta-analysis of randomized and non-randomized studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28803773" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Low-Dose Versus High-Dose Tranexamic Acid Reduces the Risk of Nonischemic Seizures After Cardiac Surgery With Cardiopulmonary Bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19996135" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : High-dose tranexamic Acid is associated with nonischemic clinical seizures in cardiac surgical patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24050855" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33316069" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Exposure-Response Relationship of Tranexamic Acid in Cardiac Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29309319" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Tranexamic Acid Dosing for Cardiac Surgical Patients With Chronic Renal Dysfunction: A New Dosing Regimen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28475557" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Understanding Potential Drug Side Effects: Can We Translate Molecular Mechanisms to Clinical Applications?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26580862" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Tranexamic acid-associated seizures: Causes and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24335749" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Tranexamic acid impairsγ-aminobutyric acid receptor type A-mediated synaptic transmission in the murine amygdala: a potential mechanism for drug-induced seizures?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23187124" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Tranexamic acid concentrations associated with human seizures inhibit glycine receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985928" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Catastrophic drug errors involving tranexamic acid administered during spinal anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30985928" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Catastrophic drug errors involving tranexamic acid administered during spinal anaesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31613811" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353044" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31576396" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : 2019 EACTS/EACTA/EBCP guidelines on cardiopulmonary bypass in adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29029990" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34217578" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : STS/SCA/AmSECT/SABM Update to the Clinical Practice Guidelines on Patient Blood Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30928282" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : What's New in Cardiopulmonary Bypass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29174746" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Evaluating the Effect on Mortality of a No-Tranexamic acid (TXA) Policy for Cardiovascular Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20870423" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : ε-Aminocaproic acid and clinical value in cardiac anesthesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28858904" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tranexamic Acid Administration During On-Pump Cardiac Surgery: A Survey of Current Practices Among Canadian Anesthetists Working in Academic Centers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25214649" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Efficacy and safety of tranexamic acid versusϵ-aminocaproic acid in cardiovascular surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31743178" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Tranexamic Acid for Acute Hemorrhage: A Narrative Review of Landmark Studies and a Critical Reappraisal of Its Use Over the Last Decade.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22397329" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25950230" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Antifibrinolytic Therapy for Cardiac Surgery: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16427545" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9416723" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
